Please login to the form below

Evotec

This page shows the latest Evotec news and features for those working in and with pharma, biotech and healthcare.

Novo Nordisk and Evotec ink drug development deal

Novo Nordisk and Evotec ink drug development deal. Will develop drugs for obesity and diabetes. ... Novo on the other hand, will hone in on Evotec’s INDiGO platform to move the selected candidates through pre-clinical testing.

Latest news

Daily Brief: DeepMind and NHS success in AI eyecare, Bayer invests in COPD, Alecensa OK in Scotland

As part of the collaboration, Bayer receives an exclusive licence to worldwide rights to programmes developed by Haplogen and Evotec. ... Undisclosed upfront payment and potential milestone and royalty-based payments will also be paid by Haplogen to
Sanofi poaches Peugeot's finance head

On top of this, Sanofi is also re-shaping its pipeline after it made a deal to transfer its anti-invectives unit to biotech Evotec.
Evotec says Sanofi deal makes it anti-infectives powerhouse

unit to become an open science focal point – bringing together other “companies, foundations, academia, and government agencies, ”says Evotec. ... That essentially means getting other research groups to put drug candidates through Evotec’s R&D
Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more

BIG BIOTECH. Celgene expands drug discovery alliance with Evotec. Celgene is experiencing a rollercoaster 2018, with late-stage drug setbacks, the departure of senior executives, and investor pressure to improve its ... Evotec has built a reputation for
Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more

BIG BIOTECH. Celgene expands drug discovery alliance with Evotec. Celgene is experiencing a rollercoaster 2018, with late-stage drug setbacks, the departure of senior executives, and investor pressure to improve its ... Evotec has built a reputation for

More from news
Approximately 12 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Pharma deals continue to slide

For example, Evotec, the German small molecule development company, is acquiring for $300m the US preclinical development company, Aptuit. ... 400. Aptuit (US). Evotec (DE). Company acquisition. Drug discovery and development to IND submission including
Deal Watch December 2016

320. Evotec (Germany). Celgene (US). Discovery collaboration. Induced pluripotent stem cells for neurodegenerative diseases. ... upfront. And although the upfronts are a modest percentage of the headline figure, ranging from < 1% (BioInvent) to 15%
Pharma deals in August 2015

Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell modulating treatments for diabetes. ... Acquisition ‐ company. 300. Aperion Biologics Evotec. Sanofi. To develops mall molecule immuno‐ therapies.
Deal Watch table for December 2014

Company acquisition. 375. Evotec / Sanofi. R&D alliance to progress Sanofi discovery phase compounds to preclinical stage (inc Sanofi discovery facility with 200 scientists).
Deal Watch table for November 2013

130. Evotec /Janssen. R&D collaboration. Target AD collaboration to identify novel therapies for Alzheimer's.

More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.

Latest appointments

Apitope strengthens its board with new director

He has also served on several boards including Ablynx, Evotec and Acambis.
Evotec CEO Werner Lanthaler temporarily stands down

Evotec CEO Werner Lanthaler temporarily stands down. Cites health reasons. Evotec's CEO Dr Werner Lanthaler, has temporarily stood down from his role within the company due to health reasons.

More from appointments
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Freelance Account Manager / Senior Account Manager - Medical Edu...: £300 per day

Medical Writers: Competitive Salary and Benefits

Senior Account Director development role to Business Director, H...: Excellent package

Account Manager, Healthcare Public Affairs: £32, 000 – £40, 000 benefits

Account Director: £48, 000 - £60, 000

Account Director: Excellent benefits

SAM – Health Behaviour/ Patient Adherence Healthcare Agency: Salary TBC

Project / Account Manager (Medical Education): Salary TBC

Medical/ Scientific Director: Salary TBC

Medical Writer – Health Behaviour/ Patient Adherence Agency: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Account Manager: Negotiable

Senior Account Managers - Oxfordshire: Attractive salary and benefits package offered

SENIOR MEDICAL WRITER IN ONCOLOGY: Up to £60, 000.00 pension bonus

Digital Manager, London – Healthcare Brandcomms, Medcomms, PR: Excellent package

Associate Director, Market Access & HEOR – North-West: Negotiable

Associate Editorial Director – Med Comms – London: Salary TBC

Production Manager – Healthcare Communications: DOE

Senior Medical Writer: Competitive Salary

Senior Account Executive, London, Medical Communications: Excellent package

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Senior Medical Writer: Great salary and benefits

Consultant Health Economics - London / Oxford: Negotiable

Senior Systematic Review Analyst - Oxford: Negotiable

Associate Director: £75, 000-90, 000

Subscribe to our email news alerts

PMHub

Add my company

Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health: For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
Innovation in merger control and the impact on the pharmaceutical sector: Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think: Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...